Faulty cellular membrane 'mix' linked to Parkinson's disease

March 15, 2018, Johns Hopkins University School of Medicine
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

Working with lab-grown human brain cells, Johns Hopkins researchers report they have uncovered a much sought-after connection between one of the most common genetic mutations in Parkinson's disease and the formation of fatty plaques in the brain thought to contribute to the destruction of motor neurons that characterize the disease.

The mutation occurs in a gene that holds the code for GBA1, an enzyme that metabolizes in the cell, which make up most of brain cell membranes. The researchers believe that changes in the mixture of fatty molecules cause protein pieces to stick together in the brain, forming "dead zones" in the brain known as Lewy bodies, which can negatively affect movement, learning and behavior.

A summary of the work was published Jan. 8 in the Proceedings of the National Academy of Sciences.

"We believe this study gives us a better understanding of the effects of GBA1 mutation and its role in the development and progress of Parkinson's disease," says Han Seok Ko, Ph.D., associate professor of neurology at the Johns Hopkins University School of Medicine Institute for Cell Engineering.

According to Ko, Lewy bodies are made of clumps of proteins known as α-synucleins. In , single α-synuclein proteins tether together in groups of four, called tetramers, which are more resistant to aggregating in the brain. However, in Parkinson's disease, single α-synucleins stick together in the cell membranes, making it impossible for neurons to properly communicate with one another.

The cellular membrane is like a mosaic where fatty molecules act as the cement that holds proteins in an intricate design. In healthy , GBA1 ensures that the "cement" is mixed properly to hold the mosaic together. Ko says he and his team theorized that when GBA1 is mutated, this process goes awry and the cell membrane's composition is changed—determining whether the α-synuclein tetramers can stay in place.

To test this theory, Ko and his team studied the effects of removing GBA1 in lab-grown human neuron cells using CRISPR-Cas9, a gene editing technology. They treated half of the "edited" cells with miglustat, a drug primarily used to block the production of fatty molecules, and observed the protein levels in the cell.

The researchers found that deleting GBA1 increased levels of a particular fatty molecule called glucosylceramide. When glucosylceramide levels rose, they reported, the number of stable α-synuclein tetramers fell. The levels returned to nearly normal with miglustat treatment.

Ko and his team believe that increased levels of glucosylceramide destabilized the cellular membrane mix and caused α-synuclein tetramers to fall out of the mosaic and break into single α-synucleins.

"This is interesting because past studies focused on how GBA1 mutations caused single α-synuclein aggregation, but not its effects on the stable tetramers," says Ko.

The researchers then tested their idea in human neurons collected from patients with GBA1-associated Parkinson's disease and found that—like the lab-grown cells—the human Parkinson's disease cells had about two times more glucosylceramide in their membranes than cells without the Parkinson's mutation. Similarly, the number of single α-synucleins also increased in these cells, and treatment with miglustat effectively restored α-synuclein tetramers to near-normal levels.

In a final test, the researchers wanted to investigate whether replacing GBA1 could restore the function of the membrane mix. After using a virus engineered to add a functional copy of the GBA1 gene into cells, Ko found that ?-synuclein tetramers returned to near-normal levels and the amount of α-synuclein aggregates was reduced.

In the future, the researchers intend to further investigate the impact the GBA1 protein has on the formation of α-synuclein tetramers and overall neuronal health.

First observed in 2004, GBA1-associated Parkinson's disease is the most common of the currently known Parkinson's disease mutations. According to the researchers, 5 to 10 percent of Parkinson's disease patients carry a GBA1 mutation.

Explore further: Mechanism behind common Parkinson's mutation discovered

More information: Sangjune Kim et al. GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1700465115

Related Stories

Mechanism behind common Parkinson's mutation discovered

February 5, 2018
Northwestern Medicine investigators have discovered how a gene mutation results in buildup of a toxic compound known to cause Parkinson's disease symptoms, defining for the first time the mechanism underlying that aspect ...

Calcium may play a role in the development of Parkinson's disease

February 19, 2018
Researchers have found that excess levels of calcium in brain cells may lead to the formation of toxic clusters that are the hallmark of Parkinson's disease.

Shedding a tear may help diagnose Parkinson's disease

February 22, 2018
Tears may hold clues to whether someone has Parkinson's disease, according to a preliminary study released today that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to ...

Stemming the flow: Stem cell study reveals how Parkinson's spreads

February 18, 2016
Stem cell research published today offers up new clues as to how Parkinson's spreads from cell to cell, a process which has evaded researchers for decades.

Researchers uncover culprit in Parkinson's brain cell die-off

March 5, 2018
An estimated 10 million people worldwide are living with Parkinson's disease—an incurable neurodegenerative disorder that leads to an increasing loss of motor control.

Study uncovers cause of cell death in Parkinson's disease

February 26, 2018
A University of Guelph researcher has discovered one of the factors behind nerve cell death in Parkinson's disease, unlocking the potential for treatment to slow the progression of this fatal neurodegenerative disorder.

Recommended for you

The eyes may have it, an early sign of Parkinson's disease

August 16, 2018
The eyes may be a window to the brain for people with early Parkinson's disease. People with the disease gradually lose brain cells that produce dopamine, a substance that helps control movement. Now a new study has found ...

First-of-its-kind Parkinson's biomarker guidelines invigorates drive for treatments

August 15, 2018
Parkinson's disease affects more than 4 million people worldwide, with numbers projected to double in the next few decades. With no known cure, there is a race for treatments to slow or stop the progression of the disease. ...

Study identifies chaperone protein implicated in Parkinson's disease

August 13, 2018
Reduced levels of a chaperone protein might have implications for the development and progression of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia, according to new research from investigators ...

Function of gene mutations linked to neurological diseases identified

August 10, 2018
Several gene mutations have been linked to Parkinson's disease, but exactly how and where some of them cause their damage has been unclear. A new Yale study, published in the Journal of Cell Biology, shows that one of the ...

Biomarkers link fatigue in cancer, Parkinson's

August 9, 2018
Biological markers responsible for extreme exhaustion in patients with cancer have now been linked to fatigue in those with Parkinson's disease, according to new research from Rice University.

Researchers examining Parkinson's resilience

August 2, 2018
Diseases have a spectrum of risk, even those partially embedded in genes such as Parkinson's disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.